Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. Among authors: sommerer c. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators. Budde K, et al. Among authors: sommerer c. Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Lancet. 2011. PMID: 21334736 Clinical Trial.
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: sommerer c. Am J Transplant. 2012 Jun;12(6):1528-40. doi: 10.1111/j.1600-6143.2012.03994.x. Epub 2012 Mar 5. Am J Transplant. 2012. PMID: 22642473 Free article. Clinical Trial.
A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.
Arns W, Sommerer C, Glander P, Ariatabar T, Porstner M, May C, Paulus EM, Shipkova M, Fischer W, Liefeldt L, Hackenberg R, Schemmer P, Domhan S, Zeier M, Budde K. Arns W, et al. Among authors: sommerer c. Clin Nephrol. 2013 Jun;79(6):421-31. doi: 10.5414/CN107908. Clin Nephrol. 2013. PMID: 23611518 Clinical Trial.
Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
Russ GR, Tedesco-Silva H, Kuypers DR, Cohney S, Langer RM, Witzke O, Eris J, Sommerer C, von Zur-Mühlen B, Woodle ES, Gill J, Ng J, Klupp J, Chodoff L, Budde K. Russ GR, et al. Among authors: sommerer c. Am J Transplant. 2013 Jul;13(7):1746-56. doi: 10.1111/ajt.12251. Epub 2013 May 13. Am J Transplant. 2013. PMID: 23668931 Free article. Clinical Trial.
Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N, Sandig C, Sommerer C, Hinz U, Giese T, Stremmel W, Zahn A. Steinebrunner N, et al. Among authors: sommerer c. Ann Transplant. 2014 Jan 22;19:32-40. doi: 10.12659/AOT.889809. Ann Transplant. 2014. PMID: 24457606 Free article. Clinical Trial.
185 results